9 -9 (59) 2023 — Oblokulov A.R.,Kholov V.A. — DETERMINATION OF THE RELATIONSHIP BETWEEN THE SEVERITY OF COVID-19 AND NON-ALCOHOLIC FATTY LIVER DISEASE

DETERMINATION OF THE RELATIONSHIP BETWEEN THE SEVERITY OF COVID-19 AND NON-ALCOHOLIC FATTY LIVER DISEASE

Oblokulov A.R., Bukhara State Medical Institute named after Abu Ali ibn Sina

Kholov V.A. Bukhara Regional Infectious Diseases Hospital

Resume

This guideline summarizes literature and our own data on the role of studying the association of non-alcoholic fatty liver disease with severe COVID-19.

Determining the relationship of non-alcoholic fatty liver disease with severe COVID-19 in the early period of the development of this viral disease can help to conduct timely complex conservative degree-related therapy in order to improve the metabolism of carbohydrate and lipid metabolism, followed by an improvement in the patient’s general condition at the recovery stage of clinical improvement.

Key words: COVID-19, liver, aspartate aminotransferase, glycated hemoglobin, alanine aminotransferase

First page

46

Last page

51

For citation: Oblokulov A.R.,Kholov V.A. – DETERMINATION OF THE RELATIONSHIP BETWEEN THE SEVERITY OF COVID-19 AND NON-ALCOHOLIC FATTY LIVER DISEASE //New Day in Medicine 2023 9(59): 46-51 https://newdaymedicine.com/index.php/2023/09/05/l-347/

LIST OF REFERENCES:

1. Lloyd-Jones G, Molayem S, Pontes CC, et al. The COVID-19 Pathway: A Proposed Oral-Vascular-Pulmonary Route of SARS-CoV-2 Infection and the Importance of Oral Healthcare Measures. J Oral Med and Dent Res. 2021;2(1):1-25.
2. World Health Organization – Weekly operational update on COVID-19 – 8 February 2022. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—8-february-2022.
3. Husenova Z.Z, Oblokulov A.R. (2021). Clinical and epidemiological characteristics of patients with severe form of COVID-19. //Central Asian Journal of Medical and Natural Science, 2021;2(3):282-285.
4. Gao F, Zheng KI, Wang XB, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care 2020;43:e72–e74.
5. Abdurashid Rahimovich Oblokulov, Zilola Zohirovna Husenova, Maksudjon Muzaffarovich Ergashev. (2021). Procalcitonin as an Indicator of Antibacterial Therapy in Covid-19. Annals of the Romanian Society for Cell Biology, 2021;25(3):5220–5224.
6. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–1586.
7. Ahmed M. Non-alcoholic fatty liver disease in 2015. World J Hepatol 2015; 7(11): 1450-1459.
8. Nseir WB, Mograbi JM, Amara AE, et al.. Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia. //QJM. 2019;112:95–99.
9. Lee CH, Choi SH, Chung GE, Park B, Kwak MS. Nonalcoholic fatty liver disease is associated with decreased lung function. //Liver Int. 2018;38:2091–2100.
10. Пинчук Т.В., Орлова Н.В., Суранова Т.Г., Бонкало Т.И. Механизмы поражения печени COVID-19. Медицинский алфавит. Коморбидные состояния 2020;19(1):39-45.
11. Малявин А.Г., Адашева Т.В., Бабак С.Л. и др.   Медицинская реабилитация больных, перенесших COVID‑19 инфекцию. Методические рекомендации. 2020;5:1-48.
12. Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. Nov 2020;73(5):1231-1240.
13. Карасева Александра Александровна, Евдокимова Наталья Евгеньевна, Худякова Алена Дмитриевна и др. “Неалкогольная жировая болезнь печени и метаболические нарушения печени при новой коронавирусной инфекции” //Сибирский научный медицинский журнал, 2021;41(6):68-75.
14. Cheong J. et al. Gastrointestinal and liver manifestations of COVID‑19. // Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2020;26(5):226-232.
15. Левитова Д.Г., Грачева С.А., Самойлов А.С. и др. Вопросы безопасности лекарственной терапии COVID-19. Архивъ внутренней медицины. 2020;10(3):165-187.
16. Ивашкин В.Т., Шептулин А.А., Зольникова О.Ю. и др.  Новая коронавирусная инфекция (COVID-19) и система органов пищеварения. //Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(3):7–13.
17. OblokulovA.R., Niyozov G.E. (2020). Clinical and epidemiological characteristics of patients with COVID-19 // International Journal of Pharmaceutical Research, 2020;12(4)3749-3752.
18. Винокуров А.С., Никифорова М.В., Оганесян А.А., и др. COVID-19. Поражение печени — особенности визуализации и возможные причины // Медицинская визуализация. 2020;24(3):26–36.